摘要
目的探讨影响年轻乳腺癌患者新辅助化疗后病理完全缓解(pCR)与预后的因素。方法回顾性分析行新辅助化疗的145例年轻乳腺癌患者临床资料,分析影响年轻乳腺癌患者新辅助化疗后pCR与预后的因素。结果145例年轻乳腺癌患者新辅助化疗后pCR率为34.48%。ER阳性、PR阳性、临床N分期、Ki67阳性、化疗方案与pCR有关(P<0.05),HER-2、化疗周期、分子分型、临床T分期与pCR无关(P>0.05);多因素分析显示,Ki67阳性、临床N分期是影响年轻乳腺癌患者新辅助化疗后pCR的独立因素(P<0.05且OR>1)。145例年轻乳腺癌患者新辅助化疗后1年复发率37.93%。ER阳性、PR阳性、临床T分期、临床N分期、pCR与新辅助化疗后预后有关(P<0.05),HER-2、Ki67、化疗方案、化疗周期、分子分型与新辅助化疗后预后无关(P>0.05);多因素分析显示,临床T分期、pCR是影响年轻乳腺癌患者新辅助化疗后预后的独立因素(P<0.05且OR>1)。结论Ki67阳性、临床N分期是影响年轻乳腺癌患者新辅助化疗后pCR的独立因素,而临床T分期、pCR是影响预后的独立因素。
Objective To explore the factors influencing the pathological remission(pCR) and prognosis of young breast cancer patients after neoadjuvant chemotherapy.Methods The clinical data of 145 young breast cancer patients treated with neoadjuvant chemotherapy were retrospectively analyzed,the factors affecting the pCR and prognosis of young breast cancer patients after neoadjuvant chemotherapy were analyzed.Results The pCR rate of 145 young breast cancer patients after neoadjuvant chemotherapy was 34.48%,ER positive,PR positive,clinical N stage,Ki67 positive,chemotherapy regimen were related to pCR,(P0.05);Multivariate analysis showed,Ki67 positive,clinical N stage were high risk factors affecting the pCR of young breast cancer patients after neoadjuvant chemotherapy(P0.05);Multivariate analysis showed,clinical T staging and pCR were high risk factors affecting the prognosis of young breast cancer patients after neoadjuvant chemotherapy(P<0.05 and OR<1).Conclusion Ki67 positive,clinical N staging are high risk factor affecting the pCR of young breast cancer patients after neoadjuvant chemotherapy,while clinical T staging and pCR are high risk factors affecting prognosis.
作者
秦媛
郭广成
薛茗予
姚晓燕
高雁歌
毕瑞瑾
QIN Yuan;GUO Guangcheng;XUE Mingyu(The First Affiliated Hospital of Zhengzhou University,Zhengzhou,450000)
出处
《实用癌症杂志》
2022年第10期1706-1709,共4页
The Practical Journal of Cancer
基金
河南省科技攻关计划(编号:201945006)。
关键词
新辅助化疗
年轻乳腺癌
病理完全缓解
预后
影响因素
Neoadjuvant chemotherapy
Young breast cancer
Complete pathological remission
Prognosis
Influencing factors
